- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10.02. | Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH | ||
| 10.02. | Kineta sells Genentech and Merck deals to investor ahead of TuHURA merger | ||
| 10.02. | Pliant pauses phase 2 lung fibrosis trial on advice of safety committee | ||
| 07.02. | New AI-discovered protein compounds kill bacteria and fungi infecting mice: study | ||
| 07.02. | eGenesis announces 2nd pig kidney procedure success, as xenotransplantation field moves forward | ||
| 07.02. | Illumina posts mixed earnings report while dealing with China tariff fallout | ||
| 07.02. | After phase 3 miss, Relmada picks up midstage Tourette's asset from Swedish biotech | ||
| 07.02. | Bristol Myers backs out of Dupixent fight, axing allergy asset despite phase 3 win | ||
| 07.02. | Acelyrin to be absorbed into Alumis in all-stock merger | ||
| 07.02. | Novo Nordisk adds pediatric data to bulging bag of evidence on near-approval hemophilia A prospect | ||
| 07.02. | CF-focused Sionna goes public in $135M IPO, while Aardvark Therapeutics plots $103M listing | ||
| 06.02. | Cancer vaccine prevents recurrence of advanced kidney cancer in small trial | ||
| 06.02. | Eli Lilly's next R&D focus: Testing incretin meds in neuro, immunology fields | ||
| 06.02. | BD bids farewell to its diagnostic, bioscience divisions with company split | ||
| 06.02. | LinusBio to launch autism diagnostic aid using a single strand of hair | ||
| 06.02. | Pfizer builds out oncology team with appointment of Novartis vet Jeff Legos | ||
| 06.02. | Kura and Kyowa hail phase 2 win for leukemia drug soon heading to FDA, but hold back data | ||
| 06.02. | Eli Lilly lops Alzheimer's and obesity assets from pipeline in Q4 update | ||
| 06.02. | X4 lays off 30% of staff, halts preclinical R&D to focus on Xolremdi rollout | ||
| 06.02. | AstraZeneca resets big bets, taking $1B in charges as ex-Alexion, Fusion assets suffer setbacks | ||
| 05.02. | Glucotrack's 3-year diabetes sensor implant clears initial human safety trial | ||
| 05.02. | Boston Scientific clocks over $1B in Farapulse revenue for the afib therapy's first year | ||
| 05.02. | 'Tough but necessary decisions': Frontier Medicines lays off staff to streamline operations | ||
| 05.02. | Qlaris sees double as drug reduces eye pressure in pair of phase 2 trials | ||
| 05.02. | Novo flunks kidney disease trial, again linking obesity prospect to neuropsychiatric side effects |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
